- Home
- CPIX vs PRLD Comparison
CPIX vs PRLD Comparison
Compare CPIX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPIX
- PRLD
- Stock Information
- Founded
- CPIX 1999
- PRLD 2016
- Country
- CPIX United States
- PRLD United States
- Employees
- CPIX N/A
- PRLD N/A
- Industry
- CPIX Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- CPIX Health Care
- PRLD Health Care
- Exchange
- CPIX Nasdaq
- PRLD Nasdaq
- Market Cap
- CPIX 43.8M
- PRLD 44.0M
- IPO Year
- CPIX 2009
- PRLD 2020
- Fundamental
- Price
- CPIX $3.13
- PRLD $0.87
- Analyst Decision
- CPIX
- PRLD Strong Buy
- Analyst Count
- CPIX 0
- PRLD 2
- Target Price
- CPIX N/A
- PRLD $4.50
- AVG Volume (30 Days)
- CPIX 78.0K
- PRLD 136.7K
- Earning Date
- CPIX 08-05-2025
- PRLD 08-14-2025
- Dividend Yield
- CPIX N/A
- PRLD N/A
- EPS Growth
- CPIX N/A
- PRLD N/A
- EPS
- CPIX N/A
- PRLD N/A
- Revenue
- CPIX $42,071,813.00
- PRLD $7,000,000.00
- Revenue This Year
- CPIX N/A
- PRLD N/A
- Revenue Next Year
- CPIX N/A
- PRLD N/A
- P/E Ratio
- CPIX N/A
- PRLD N/A
- Revenue Growth
- CPIX 11.34
- PRLD N/A
- 52 Week Low
- CPIX $1.04
- PRLD $0.61
- 52 Week High
- CPIX $7.25
- PRLD $5.95
- Technical
- Relative Strength Index (RSI)
- CPIX 44.65
- PRLD 51.23
- Support Level
- CPIX $2.75
- PRLD $0.75
- Resistance Level
- CPIX $3.49
- PRLD $0.96
- Average True Range (ATR)
- CPIX 0.35
- PRLD 0.09
- MACD
- CPIX -0.02
- PRLD 0.01
- Stochastic Oscillator
- CPIX 31.45
- PRLD 48.00
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.